|Videos|November 14, 2017

How Are Current Infection Control Measures Falling Short Against C. difficile?

Barley Chironda, RPN, CIC, discusses current infection control measures taken to prevent C. difficile and the reasons why they are falling short.

Barley Chironda, RPN, CIC, infection control specialist at Clorox Healthcare, explains current infection control measures taken to prevent C. difficile and the reasons why they are falling short.

Interview Transcript (modified slightly for readability):

“Some infection control strategies that I use in health care settings right now, I would lump into three buckets. First off, there’s hand hygiene, which is the washing of hands, and that has to be done every single time that you come into contact with a patient. I’ll speak to some of the complications that are being faced. The other thing that goes on is antimicrobial stewardship, so that’s the use of proper antibiotics at every single point in time so that you don’t use them irresponsibly. Then thirdly, is the disinfection processes that are done on every single surface of the hospital setting. And so, these are three buckets.

In terms of where are we falling short? Really, I think, there’s a lot of work that needs to be done every single time a health care worker leaves a room, and for the pressure that’s there around the turnaround time, the pressure of all the resources, it creates a lot of complications. And so, I would say the one big thing that’s really there right now is there is so much pressure to do good work that it falls through the cracks in the system.”


Related to this article

Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.
LMN-201 Reduces C difficile Recurrence
In the phase 2 RePreve trial, Lumen Bioscience’s investigational oral biologic LMN-201 plus standard antibiotics achieved global cure in 83.3% of patients with C difficile infection vs 36.4% with placebo, and cut recurrence sixfold (9.1% vs 55.6%) with no drug-related serious adverse events.